Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 1 1

Status

Completed 2

Sponsor Class

OTHER 2INDUSTRY 2NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2

Conditions

Hodgkin Disease 27Lymphoma 22Hematologic Diseases 20Lymphoma, Large-Cell, Anaplastic 16Lymphoma, Non-Hodgkin 11Recurrence 5Lymphoma, T-Cell, Peripheral 5Lymphoma, T-Cell 5Lymphoma, Large B-Cell, Diffuse 5Lymphoma, B-Cell 4Lymphoma, T-Cell, Cutaneous 3Squamous Cell Carcinoma of Head and Neck 2Neoplasms 2Melanoma 2Lymphoma, Primary Cutaneous Anaplastic Large Cell 2Dendritic Cell Sarcoma, Interdigitating 2Carcinoma, Non-Small-Cell Lung 2Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Sarcoma, Kaposi 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Ovarian Neoplasms 1Neoplasms by Histologic Type 1Myelodysplastic Syndromes 1Mycosis Fungoides 1Lymphoproliferative Disorders 1Lymphomatoid Papulosis 1

Interventions

pembrolizumab 133Gemcitabine 101Paclitaxel 100Carboplatin 84Nivolumab 66Docetaxel 62Bevacizumab 62Cisplatin 57Pemetrexed 50Fluorouracil 49Cyclophosphamide 41Cetuximab 41trametinib 38venetoclax 37Leucovorin 37Irinotecan 37Sorafenib 35Capecitabine 35Ipilimumab 33Dexamethasone 32atezolizumab 31Erlotinib Hydrochloride 28130-nm albumin-bound paclitaxel 28Drug Therapy 27Epoetin Alfa 26Doxorubicin 25Oxaliplatin 24Albumin-Bound Paclitaxel 24Prednisone 23Rituximab 22

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Neoplasms × Brentuximab Vedotin × Clear all
NCT01990534 2021-04-09

A Study of Brentuximab Vedotin in Participants With Relapsed or Refractory Hodgkin Lymphoma

Takeda

Phase 4 Completed
60 enrolled 21 charts
Lymphoid

Hematologic Diseases, Hodgkin Disease, Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Lymphoproliferative Disorders, Neoplasms, Neoplasms by Histologic Type, Recurrence, Lymphoma, B-Cell, Lymphoma, T-Cell, Lymphoma, Large B-Cell, Diffuse

NCT01026415 2014-12-18

Clinical Pharmacology Study of Brentuximab Vedotin (SGN-35)

Seagen Inc.

Phase 1 Completed
73 enrolled
Lymphoid

Carcinoma, Hematologic Diseases, Hodgkin Disease, Lymphoma, Lymphoma, Non-Hodgkin, Neoplasms, Lymphoma, Large-Cell, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡